AMF Tjanstepension AB Trims Stock Holdings in IDEXX Laboratories, Inc. $IDXX

AMF Tjanstepension AB decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 92.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 2,092 shares of the company’s stock after selling 24,325 shares during the quarter. AMF Tjanstepension AB’s holdings in IDEXX Laboratories were worth $1,415,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in IDXX. Elyxium Wealth LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at approximately $3,666,459,000. Northwestern Mutual Wealth Management Co. boosted its stake in IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock valued at $977,210,000 after buying an additional 1,442,174 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in IDEXX Laboratories by 41.7% during the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after buying an additional 605,290 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in IDEXX Laboratories by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after buying an additional 326,348 shares during the last quarter. Finally, Zurich Insurance Group Ltd FI bought a new position in IDEXX Laboratories during the third quarter valued at approximately $143,730,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $545.79 on Tuesday. IDEXX Laboratories, Inc. has a 52-week low of $496.61 and a 52-week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The firm has a market capitalization of $43.05 billion, a P/E ratio of 40.19, a P/E/G ratio of 3.07 and a beta of 1.58. The stock has a 50 day moving average price of $570.62 and a 200 day moving average price of $644.92.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period last year, the business posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of recent research reports. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. UBS Group decreased their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Citigroup initiated coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Finally, Piper Sandler decreased their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the transaction, the chief executive officer directly owned 83,606 shares in the company, valued at $54,975,125.30. This trade represents a 21.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Nimrata Hunt sold 2,693 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the transaction, the executive vice president owned 19,899 shares in the company, valued at $13,163,984.46. The trade was a 11.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 27,777 shares of company stock worth $18,235,113 over the last 90 days. 0.79% of the stock is currently owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.